RESUMEN

Fifteen novel arylimidamides (AIAs) (6 bis-amidino and 9 mono-amidino analogues) were assayed against Trypanosoma cruzi in vitro and in vivo. All the bis-AIAs were more effective than the mono-AIAs, and two analogues, DB1967 and DB1989, were further evaluated in vivo. Although both of them reduced parasitemia, protection against mortality was not achieved. Our results show that the number of amidino-terminal units affects the efficacy of arylimidamides against T. cruzi.

Asunto(s)

Amidinas/uso terapéutico , Enfermedad de Chagas/tratamiento farmacológico , Parasitemia/tratamiento farmacológico , Tripanocidas/uso terapéutico , Trypanosoma cruzi/efectos de los fármacos , Amidinas/química , Animales , Enfermedad de Chagas/mortalidad , Enfermedad de Chagas/parasitología , Masculino , Ratones , Parasitemia/mortalidad , Parasitemia/parasitología , Pruebas de Sensibilidad Parasitaria , Tripanocidas/química